NeuroMetrix Device Receives Breakthrough Designation From FDA

The innovative NeuroMetrix Quell device was granted Breakthrough Designation by the FDA, causing NURO price to jump 45% to $7.16 on January 18. Prior to this event, the worth had been stable for the last two weeks. Yesterday the trading session was closed at $6.35 with a trading volume of $64,316,957.

NeuroMetrix makes a huge contribution to modern medicine by developing products designed to detect and study diseases of the peripheral nervous system and spinal cord. Its list of products includes Quell, a device for pain relief for people undergoing chemotherapy; DPNCheck, a qualitative test for the evaluation of systemic neuropathies; ADVANCE, a device used by orthopedic surgeons to evaluate a patient’s disease.


Many patients who have completed chemotherapy suffer from CIPN, which is accompanied by debilitating pain, cramps, numbness, impaired balance, and walking. As a rule, it lasts 3-6 months after completion of chemotherapy. Thanks to Breakthrough Designation, Quell will be evaluated and developed in an accelerated manner so that patients have access to it as soon as possible without compromising their health.